Where is the Human Papillomavirus vaccine heading? A Review

Authors : Burcu Parlak

Pages : 280-285

View : 63 | Download : 99

Publication Date : 2024-09-25

Article Type : Review Paper

Abstract :DNA oncogenic viruses include Human papillomavirus that causes epithelial proliferation at cutaneous and mucosal surfaces. Human papillomavirus is the most common sexually transmitted infection. It spreads through contact between the skin or mucosa also enters the body through cutaneous or mucosal damage. Vertical transfer from mother to baby during birthing is a possibility but is uncommon. Human papillomavirus infection can result in cancer even though it is usually asymptomatic and readily treated by the immune system. Cancers of the head and neck mucosal regions, cervical, and anogenital areas are examples of malignant lesions associated with Human papillomavirus. It is also linked to non-cancerous disorders such recurrent respiratory papillomatosis and ano-genital warts. Globally, both men and women have an equal chance of contracting the infection at least once in their lifetime. The most important protection methods against Human papillomavirus are education and immunization. It is estimated that within a few decades, countries with effective national HPV vaccination programs will have eliminated cervical cancer. Cervical cancer remains a leading source of morbidity and mortality in underdeveloped countries without systematic screening and HPV immunization programs. In Turkey, cervical cancer screening is a routine procedure, and research is ongoing by the Ministry of Health to include Human papillomavirus vaccine in the national immunization schedule. In addition to discussing some of the challenges faced in achieving universal Human papillomavirus vaccination coverage and, consequently, the eradication of cervical cancer, this review seeks to increase awareness of efficiency, and safety of the Human papillomavirus vaccine.
Keywords : Human papillomavirus, serviks kanseri, HPV aşıları